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ABSTRACT 
The present work demonstrates a novel concept for intratumoral chemo-radio 
combination therapy for locally advanced solid tumors. For some locally advanced tumors, 
chemoradiation is currently standard of care. This combination treatment can cause acute and 
long term toxicity that can limit its use in older patients or those with multiple medical 
comorbidities. Intratumoral chemotherapy has the potential to address the problem of systemic 
toxicity that conventional chemotherapy suffers, and may, in our view, be a better strategy for 
treating certain locally advanced tumors. The present study proposes how intratumoral 
chemoradiation can be best implemented. The enabling concept is the use of a new 
chemotherapeutic formulation in which chemotherapy drugs (e.g., paclitaxel (PTX)) are co-
encapsulated with radioluminecsnt nanoparticles (e.g., CaWO4 (CWO) nanoparticles (NPs)) 
within protective capsules formed by biocompatible/biodegradable polymers (e.g., poly(ethylene 
glycol)-poly(lactic acid) or PEG-PLA). This drug-loaded polymer-encapsulated 
radioluminescent nanoparticle system can be locally injected in solution form into the patient’s 
tumor before the patient receives normal radiotherapy (e.g., 30 – 40 fractions of 2 – 3 Gy daily 
X-ray dose delivered over several weeks for locally advanced head and neck tumors). Under X-
ray irradiation, the radioluminescent nanoparticles produce UV-A light that has a radio-
sensitizing effect. These co-encapsulated radioluminescent nanoparticles also enable radiation-
triggered release of chemo drugs from the polymer coating layer. The non-toxic nature (absence 
of dark toxicity) of this drug-loaded polymer-encapsulated radioluminescent nanoparticle 
(“PEG-PLA/CWO/PTX”) formulation was confirmed by the MTT assay in cancer cell cultures. 
A clonogenic cell survival assay confirmed that these drug-loaded polymer-encapsulated 
radioluminescent nanoparticles significantly enhance the cancer cell killing effect of radiation 
therapy. In vivo study validated the efficacy of PEG-PLA/CWO/PTX-based intratumoral chemo-
radio therapy in mouse tumor xenografts (in terms of tumor response and mouse survival). 
Results of a small-scale NP biodistribution (BD) study demonstrate that PEG-PLA/CWO/PTX 
NPs remained at the tumor sites for a long period of time (> 1 month) following direct 
intratumoral administration. A multi-compartmental pharmacokinetic model (with rate constants 
estimated from in vitro experiments) predicts that this radiation-controlled drug release 
technology enables significant improvements in the level and duration of drug availability within 
the tumor (throughout the typical length of radiation treatment, i.e., > 1 month) over 
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conventional delivery systems (e.g., PEG-PLA micelles with no co-encapsulated CaWO4, or an 
organic liquid, e.g., a 50:50 mixture of Cremophor EL and ethanol, as in Taxol), while it is 
capable of maintaining the systemic level of the chemo drug far below the toxic threshold limit 
over the entire treatment period. This technology thus has the potential to offer a new therapeutic 
option that has not previously been available for patients excluded from conventional 
chemoradiation protocols. 
KEYWORDS: Radioluminescent nanoparticles; radiotherapy; chemotherapy; chemoradiation; 
radiation-controlled drug release; PEG-PLA; paclitaxel; head and neck squamous cell carcinoma 
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1. INTRODUCTION 
More than 51,540 new cases of head and neck cancer were diagnosed within USA in 
2018. Out of these cases, 10,030 deaths were reported [1]. Most patients at the time of diagnosis 
are at a advanced stage, with 40% of the patients with regional lymph node involvement and 
10% with distant metastasis [2]. Currently, the treatment options for patients with locally 
advanced head and neck carcinomas consist of surgery followed by appropriate adjuvant therapy 
(with or without radiation and with or without chemotherapy), concurrent chemoradiation, 
induction chemotherapy followed by local therapy, or radiation alone [1]. 
Oropharyngeal and palliative surgeries are difficult in terms of technical approach. 
Radiation therapy given after surgery is beneficial for a few months; however, there are still high 
chances of recurrence with five-year survival rates of only 20 – 40% [3-5]. Chemotherapy, in 
general, is better tolerated than surgery followed by radiation, as drug dose and route of 
administration can be tailored depending on the patient’s condition. However, chemotherapy 
alone for head and neck cancers has not been shown to be curative, and a local therapy (surgery 
or radiation) is needed. Concurrent chemoradiation has been shown to be more effective than 
radiation alone [6]. The adverse effects of chemotherapy are well documented. In conventional 
chemotherapy, chemotherapeutic drugs are administered intravenously into the bloodstream 
periodically (alternative days, weeks, etc.) over “cycles”. In this process, the drug concentration 
in the blood varies with time between a maximum concentration (which may represent a toxic 
level) and a minimum value (which is typically below the limit at which the drug becomes 
ineffective). In each cycle, the drug concentration inside the body reaches a toxic level (referred 
as a “peak”) and then decreases after about 4 – 12 hours [5, 7, 8]. To maintain the level of the 
chemo drug in the therapeutic range, the drug is administered in multiple cycles, each with a 
dose higher than the therapeutic limit. Consequently, the drugs at such toxic level not only kill 
cancer cells but also affect the healthy tissues of the body. There are substantial short and long-
term side effects associated with systemic chemotherapy. This is due to the uncontrolled 
concentration of the drug in the body during the peaks of the chemotherapy cycles with direct 
administration of the drug. Short-term side effects include the toxic effects observed during 
chemotherapy regimen, while long-term side effects include later complications of the treatment 
arising after the completion of adjuvant chemotherapy. Depending on the individual, specific 
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agent used, amount of dose, duration of treatment in the adjuvant regimen, etc., the intensities of 
these side effects vary [9]. 
Sequential chemotherapy administration, in the form of induction chemotherapy followed 
by radiotherapy or concurrent chemoradiation, has been used for head and neck cancer [10]. A 
significant improvement in disease-free and locoregional recurrence-free survival rate has been 
observed; the survival rate has been reported to be around 50 – 60% at 5 years [11, 12]. 
However, symptoms of grade 2, 3 and even grade 4 toxicity (such as rash, fatigue, neuropathy, 
anemia, alopecia, myelosuppression, neutropenia, mucositis, immunosuppression, xerostomia, 
hypothyroidism, diarrhea, and constipation) have been observed in different clinical studies with 
systemic chemotherapy [13-16]. A recent study has reported certain changes in gut microbiota 
leading to clostridium difficile infection (CDI) in head and neck cancer patients who received 
systemic paclitaxel chemotherapy followed by radiation [17]. In addition, the multiple patient 
exclusion criteria limit the applicability of the current chemo-radio protocol to within a particular 
domain of patients. For example, patients above 70 years of age, patients associated with certain 
other medical conditions such as uncontrolled hypertension, ischemic heart disease, human 
immunodeficiency virus infection, diabetes mellitus, mental disability, chronic liver disease, or  
pulmonary tuberculosis, patients with prior or synchronous malignancy, previous radiotherapy or 
chemotherapy, pregnancy or current lactation, patients with sickle cell disease, and patients with 
distant metastasis may be excluded from the present treatment regimen [18, 19]. 
There has been a steady growth in research on intratumoral chemotherapy during the past 
few decades as an alternative to the conventional systemic delivery approach for patients with 
unresectable lesions [20, 21]. The first known clinical study of intratumoral chemotherapy was 
performed in 1958 using triethylene phosphoramide and oxapentamethylene, which  resulted in 
significant tumor regression for advanced cancers of the breast, liver and ovaries [22]. Since the 
1990s, there has been a steady increase in the development of controlled release drug delivery 
vehicles for intratumoral treatment due to its advantages over systemic therapies. Several 
formulations based on polymers, liposomes and nanoparticles have been studied as implantable 
controlled release depots, particularly, for hydrophobic drugs, such as cisplatin and paclitaxel 
[20, 21, 23, 24]. One such formulation, Gliadel™ wafers (polymer-based implants) are currently 
used clinically to treat an aggressive form of brain cancer [25]. Alternatively, recently developed  
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hafnium oxide nanoparticle radio-sensitizers are delivered via intratumoral injection for 
advanced head and neck cancers, and are currently in Phase II clinical trials [26]. Safety and 
efficacy of locally delivered chemotherapies (carmustine, carboplatin, and camptothecin) have 
been tested in combination with concurrent radiation therapy for treating metastatic brain  [27] 
and breast [28] tumors; these studies demonstrated that this local chemo-radiation combination is 
safe and effective in prolonging survival in mouse models of metastatic brain and breast cancers. 
Intratumoral administration of chemotherapeutic drugs can provide localization of the drugs 
within the tumor and can prevent exposure of the non-target organs to such drugs, resulting in 
reduced toxicity and better efficacy. It can be a promising approach not only for the treatment of 
locally advanced solid tumors but also for malignant gliomas in adjunct therapy [18, 19, 29, 
30]. Moreover, it has the potential to be an effective loco-regional therapy, especially for the 
patients who fall under the exclusion criteria of the current systemic chemo-radio therapy. 
Polymeric carrier systems are known for their biocompatible nature and ability to sustain 
delivery of drugs [31]. The poly(ethylene glycol-b-D,L-lactic acid)(PEG-PLA)-based paclitaxel 
(PTX) formulation, commercially known as Genexol-PM (or Cynviloq
TM
 in the United States), is 
an FDA-equivalent-approved example. Intratumoral pharmacokinetic studies have shown that 
the polymeric formulation can confine the drug (paclitaxel) within the tumor two times longer 
than the paclitaxel administered in the form of an organic dispersion [30]. 
Polymeric formulations release the encapsulated drug in a sustained manner. However, 
there is still need for a better means to control the drug release rate in order to maintain the 
concentration of the drug inside the tumor within the therapeutically effective range for an 
extended period of time. This need is addressed by the radiation-controlled chemo drug release 
system disclosed in the present article (Scheme 1). In this work, a novel chemo-radio 
combination therapy protocol enabled by PTX-loaded PEG-PLA-encapsulated CaWO4 (CWO) 
nanoparticles (NPs) is demonstrated. Our laboratory has been pioneering the use of CWO NPs to 
enhance cancer radiotherapy. CaWO4 is a naturally abundant radio-luminescent material 
(“scintillator”) that has been commonly used for X-ray imaging [32]. CaWO4 has a solubility 
product constant of Ksp ≈ 4.9 × 10
-10
 (at a neutral pH at 298 K) and therefore can only liberate 
non-toxic amounts of WO
−2
 ions [33]. WO
−2
 ions are typically rapidly cleared from the body by 
the kidneys [34]. CaWO4 is known to have no carcinogenic properties [35]. CWO NPs can 
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effectively be encapsulated within self-assemblies of block copolymers [35]. Recently, we have 
shown that PEG-PLA-encapsulated CaWO4 nanoparticles (PEG-PLA/CWO NPs) are promising 
as a contrast agent for X-ray imaging [36] and also as a radio-sensitizer for cancer radiation 
therapy [33]. The work described in the present manuscript is an extension of these previous 
studies aimed at developing CWO NP-based radio-sensitizers. Specifically, this work 
investigates how the incorporation of the additional therapeutic component, PTX, affects the 
radio-sensitization ability of the PEG-PLA/CWO NP system. PTX-loaded PEG-PLA/CWO NPs 
(PEG-PLA/CWO/PTX NPs) can be directly injected into solid tumor. An in vivo BD study 
confirms that following intratumoral administration, these NPs stay within the tumor for a long 
time (for at least one month). During radiotherapy, X-rays/γ rays trigger the release of 
encapsulated PTX from the polymer coating layer; controlled experiments suggest that the 
mechanism of radiation-induced PTX release involves two processes: (1) 
partitioning/accumulation of PTX in the vicinity of the CaWO4 core (causing very slow release 
of PTX in the absence of radiation), and (2) photolytic degradation of PLA (triggering rapid PTX 
release under X-ray or UV-A irradiation). PTX is a standard drug in first-line chemotherapy for 
head and neck cancer [37]. Concurrent PEG-PLA/CWO/PTX NPs produce synergistic 
interactions with X-ray/γ ray radiation due to the radiosensitization effects of PTX [11, 31, 38, 
39] and UV-A light generated by CWO NPs under X-ray/γ ray irradiation [40]. In vitro 
clonogenic and in vivo tumor suppression/mouse survival assays validate that PEG-
PLA/CWO/PTX NPs are indeed capable of inducing a significant enhancement of the tumor 
suppressive effect of X-rays. A multicompartmental PK model based on experimental rate 
constants predicts that the radiation-controlled drug release mechanism enables to maintain the 
drug concentration within the tumor at the therapeutic level for an extended period of time, while 
it also enables to maintain the drug concentration in the systemic circulation well below the toxic 
threshold; similar PK simulations performed for other PTX formulations (PTX-loaded PEG-PLA 
micelles with no co-encapsulated CaWO4, and PTX dispersed in Cremophor EL/ethanol (Taxol)) 
suggest that these conventional PTX formulations are less desirable for use in IT chemo-
radiotherapy. The present radiation-controlled chemo drug release technology is expected to 
enable intratumoral chemo-radiotherapy treatment for frail patients who do not meet the 
inclusion criteria for standard chemo-radio treatment guidelines. Intratumoral chemo-
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radiotherapy is expected to offer a treatment option that delays the progression or relapse of the 
disease without compromising the quality of life for patients. 
 
 
Scheme 1. Schematic illustration of the preparation of poly(ethylene glycol-b-lactic acid)(PEG-PLA)-encapsulated 
CaWO4 (CWO) nanoparticles (NPs) loaded with chemotherapeutic drugs, paclitaxel (PTX), and the release of PTX 
from PEG-PLA/CWO NPs upon exposure to X-rays. CWO NPs are radio-luminescent; they produce long-
wavelength UV light in the “UV-A” (320 – 400 nm) range under X-ray irradiation [35]. CWO NPs are coated with 
PEG-PLA block copolymers. PEG chains are hydrophilic and stay in the aqueous phase. The CWO NP core is 
coated with hydrophobic PLA chains. PTX is encapsulated within the hydrophobic PLA layer. Under X-ray 
irradiation, UV-A is generated by CWO NPs, and X-rays and UV-A light cause the release of PTX from the PLA 
layer into the aqueous surrounding. Intratumorally administered PEG-PLA/CWO/PTX NPs release PTX in tumor 
during radiation treatments. The PTX release rate is controlled by radiation dose. 
 
2. MATERIALS & METHODS 
2.1 Synthesis and characterizations of PEG-PLA block copolymers and CWO NPs 
The PEG-PLA block copolymer material used in this study (Mn,PEG = 5,000 Da, Mn,PLA = 
5,000 Da) was synthesized via 1,8-diazabicyclo[5.4.0]undec-7-ene(DBU)-catalyzed ring-opening 
polymerization of racemic lactide from a monomethoxy/monohydroxy-terminated  PEG macro-
initiator, as has been described in a previous publication [40]. Conversion to the PEG-PLA 
product was confirmed by 
1
H-NMR (Supplementary Material (SM) Figure S1). Primary CWO 
NPs of a monodisperse diameter (10 nm) were synthesized using a microemulsion method as 
also described in [40]. 
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2.2 Preparation and characterizations of PTX-loaded PEG-PLA-encapsulated CWO NPs 
Our laboratory has developed a procedure for preparation of PEG-PLA-encapsulated 
CWO NPs [36, 40]. This procedure was adopted to prepare PTX-loaded PEG-PLA-encapsulated 
CWO NPs (having a mean hydrodynamic diameter of about 50 nm). PTX was purchased from 
either Samyang Biopharmaceuticals (used in all studies reported in this article except for the in 
vivo CWO NP BD study described in Section 2.11) or Biotang (used in the CWO BD study). 
300 mg of PEG-PLA block copolymers (BCP) and 30 mg of PTX were dissolved in 3.8 g of 
dimethylformamide (DMF, > 99.9% purity, Sigma-Aldrich). 0.5 mg of CWO NPs (10 nm 
diameter) were dispersed in 2.1 g of Milli-Q-purified water. These two solutions were mixed 
together rapidly under simultaneous high-speed mechanical stirring (15,000 rpm) and 
ultrasonication for 30 minutes. The resultant mixture was centrifuged at 5,000 rpm (equivalent to 
3214× g, Eppendorf 5804 (F-34-6-38, radius of rotor = 11.5 cm)) for 10 minutes. The 
supernatant containing unencapsulated PTX, excess PEG-PLA and DMF was removed. The 
precipitate was dried under vacuum oven overnight. Assuming a hydrodynamic diameter of 66 
nm for PEG-PLA/CWO/PTX NPs in the 3.8:2.1 DMF/water mixture (based on data shown in 
SM Figure S2) and a composition of PEG:PLA:CWO:PTX:water = 0.65:0.65:1.0:0.12:0.65 by 
weight (see the figure caption for Figure 5) within the hydrodynamic volume of a PEG-
PLA/CWO/PTX NP, the average mass density of a PEG-PLA/CWO/PTX NP within its 
hydrodynamic volume is estimated to be 1.54 g/cc, which gives an estimate of 2.28 × 10
3
 s for 
the time it takes for a PEG-PLA/CWO/PTX NP to sediment a distance of 1.0 cm (the height of 
liquid in the centrifugation tube) at 3214× g centrifugal acceleration using the equation, τ ≈ 
9lη/(2R2Δρg), where τ is the sedimentation time, l is the sedimentation distance, η is the 
viscosity of the medium, R is the radius of the NP, Δρ is the density difference between the NP 
and medium, and g is the gravitational acceleration constant; therefore, during the 10-minute 
centrifugation time, about 26% of PEG-PLA/CWO/PTX NPs will have sedimented to the bottom 
of the vial. Similarly, assuming the same hydrodynamic diameter (≈ 66 nm, consistent with Ref. 
[41]) for PEG-PLA/PTX NPs in the DMF/water mixture and a composition of 
PEG:PLA:PTX:water = 0.65:0.65:0.12:0.65 by weight within the hydrodynamic volume of a 
PEG-PLA/PTX NP, the average mass density of a PEG-PLA/PTX NP within its hydrodynamic 
volume is estimated to be 1.12 g/cc, which gives an estimate of 9.36 × 10
3
 s for the time it takes 
for a PEG-PLA/PTX NP to sediment a distance of 1.0 cm at 3214× g centrifugal acceleration; 
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therefore, during the 10-minute centrifugation time, about 6.4% of PEG-PLA/PTX NPs will have 
sedimented to the bottom of the vial (94% of non-CWO-containing PEG-PLA/PTX NPs will 
remain in the supernatant). Therefore, it is reasonable to expect that the above centrifugation step 
removes most of the excess PEG-PLA and PTX. 
After re-dispersing PTX-loaded PEG-PLA-encapsulated CWO NPS in PBS at a NP 
concentration of 0.25 mg CWO per mL and filtering the solution with a 0.22 μm PVDF filter, 
their mean hydrodynamic size was determined by dynamic light scattering (DLS) using a 
Brookhaven Instruments ZetaPALS instrument; data presented in SM Figure S2; the mean 
hydrodynamic diameters of PEG-PLA/CWO/PTX and PEG-PLA/CWO NPs in Milli-Q water 
were 65.6 and 40.8 nm, respectively (Figure S2).. In DLS characterization, the filtration step was 
necessary to remove a very small amount of large aggregates. In all other studies discussed in 
this article, unfiltered samples were used, because filtration did not influence results; of note, 
PTX release kinetics is expected to be primarily controlled by the thickness of the PLA layer, 
which in turn is primarily controlled by the molecular weight of the PLA block (currently, study 
is underway to investigate how PEG-PLA molecular weight characteristics affect PTX release 
kinetics). The morphologies of these nanoparticles were also examined with transmission 
electron microscopy (TEM) using 2% uranyl acetate as a negative staining agent (Figure 1). 
 
 
 
Figure 1. Representative TEM micrographs of (A) PEG-PLA/CWO NPs, and (B) PEG-PLA/CWO/PTX NPs. Dried 
specimens were stained with uranyl acetate. Scale bars are 50 nm in both images. 
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2.3 In vitro drug release kinetics 
To measure the rate of PTX release from PTX-loaded PEG-PLA-coated CWO NPs, the 
dried pellet obtained from the previous step was re-dispersed in PBS at a CWO concentration of 
0.25 mg/mL, and the solution was placed in a dialysis tube (50 kDa MWCO). The dialysis tube 
was sealed at both ends, submerged in 50 mL of PBS, and kept under mild stirring using a 
magnetic stirring bar. PTX release measurements were performed on four samples: (1) X-ray-
irradiated vs. (2) non-X-ray-irradiated PTX-loaded PEG-PLA-encapsulated CWO NPs, and (3) 
X-ray-irradiated vs. (4) non-X-ray-irradiated PTX-loaded PEG-PLA micelles (with no co-
encapsulated CWO NPs). X-ray irradiation was performed at 7 Gy on Day 2 following re-
suspension in PBS. At regular intervals, 50 mL of the dialysis medium was taken for 
measurement of PTX concentration; each time the same volume of blank PBS was added to the 
medium to compensate for the volume loss. PTX was collected from the dialysis sample by 
liquid-liquid extraction as described below. 30 mL of dichloromethane (DCM, > 99.9% purity, 
Sigma-Aldrich) was added to 50 mL of the dialysis sample. This mixture was vigorously shaken 
for a few minutes, and then kept undisturbed for 30 minutes until two distinct liquid layers were 
formed. The bottom DCM solution was carefully collected and was dried under vacuum oven 
overnight. The dried substance (PTX) was dispersed in 2 mL of a 1:1 by volume mixture of 
water and acetonitrile (HPLC solvent) and analyzed by HPLC for determination of the PTX 
concentration as follows. A C18 column with dimensions 4 × 125 mm (Agilent 1100 Hypersil, 5 
µM) was used as the stationary phase. A 60:40 by volume mixture of water and acetonitrile was 
used as the mobile phase at a flow rate of 1.0 mL/min. The sample injection volume was 10 µL. 
The PTX absorbance was measured using a UV detector at 204 nm wavelength. Standard 
solutions containing different concentrations of PTX in the range of 10 – 1000 µg/mL were 
prepared from a concentrated stock solution. PTX concentrations were estimated using an 
isocratic reverse phase HPLC method. From these data, a calibration plot was prepared relating 
UV absorbance to PTX concentration (SM Figure S3). 
2.4 Drug encapsulation efficiency 
The PTX encapsulation efficiency was defined as: encapsulation efficiency (%) = 
(amount initially added – amount remaining in the supernatant after encapsulation) / (amount 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
initially added) × 100. The amount of PTX remaining in the supernatant after encapsulation was 
determined by analyzing the PTX concentration in the supernatant of the centrifuged 
encapsulation solution by the HPLC method. 
2.5 Gel permeation chromatography (GPC) characterization of PEG-PLA following 
exposure to X-rays or direct UV-A light 
0.7 mg of PEG-PLA-coated CWO (“PEG-PLA/CWO”) NPs or 0.7mg of empty (non-
CWO-loaded) PEG-PLA micelles were dispersed in 1.45 mL of PBS. These samples were 
irradiated with a single 7 Gy dose of X-rays (XRAD 320, 320 keV, 2.15 Gy/min) or UV-A lamp 
light (UVP UVGL-15, 365 nm, exposure time = 11 s, source-to-sample distance = 1 cm, UV 
fluence on sample = 2.8 J/cm
2 
(= 4 W (manufacturer information) × 11 s / (3.5 cm × 4.5 cm) 
(illuminated area))). 5 mL of DCM was added to each of these solutions to extract the PEG-PLA 
polymer from the aqueous PEG-PLA/CWO suspension. The resulting solutions were vigorously 
mixed for 10 minutes and centrifuged at 5,000 rpm (equivalent to 3214× g, Eppendorf 5804 (F-
34-6-38, radius of rotor = 11.5 cm)) for 20 minutes. The DCM-rich (bottom) phase of the 
supernatant was collected and dried in a vacuum oven at room temperature for 12 h. The 
polymer residue was dissolved in HPLC-grade tetrahydrofuran (THF), and the solution was 
filtered with a 0.22 μm PTFE filter. Both X-ray/UV-treated and non-X-ray/UV-treated polymer 
samples were analyzed using an Agilent Technologies 1200 Series GPC system equipped with a 
Hewlett-Packard G1362A refractive index (RI) detector and three PLgel 5 μm MIXED-C 
columns. THF was used as the mobile phase at 35.0 °C and a flow rate of 1 mL/min. The pristine 
PEG-PLA (not exposed to X-rays or UV-A light) was used as control. 
2.6 Cell culture 
HN31 cells were generously provided by Dr. Jeffrey N. Myers at MD Anderson Cancer 
Center [42]. HN31 cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM) 
supplemented with 10% v/v fetal bovine serum and 0.1% L-glutamine (Gibco Life 
Technologies) (as recommended by American Type Culture Collection (ATCC)) in a humidified 
incubator with 5% CO2 at 37.0 °C. Once the cell confluence reached 80%, the growth medium 
was removed, and adherent cells were washed twice with PBS (Gibco Life Technologies). Cells 
were then detached from the plates by treatment with TrypLE
TM
 Express (1×) solution for 4 – 6 
minutes at 37.0 °C. Detached cells were centrifuged at 300× g for 5 minutes at room 
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temperature. The cell pellet was resuspended in a minimal amount of growth medium (2 – 3 ml), 
and the cells were counted using a haemocytometer. These cells were plated in T-25 cm
2
 flasks 
(Corning) at a seeding density of 0.2 – 0.5 × 106 cells per mL in 5 mL growth medium. 
2.7 MTT cell viability assay 
The in vitro cytotoxicities of both uncoated CWO NPs (10 nm diameter determined by 
TEM [35, 36]) and PEG-PLA-coated CWO NPs (50 nm hydrodynamic diameter determined by 
DLS) in HN31 cells were evaluated using the MTT assay procedure described in the literature 
[43]. HN31 cells in the exponential growth phase were seeded in a flat-bottom 96-well 
polystyrene-coated plate at a seeding density of 0.5 × 10
4
 cells per well, and incubated for 24 
hours at 37.0 °C in a 5% CO2 incubator prior to exposure to CWO NPs. Cells were then treated 
with various concentrations of PEG-PLA-coated and uncoated CWO NPs (0.16, 0.32, 0.63, 1.25, 
2.5 and 5.0 mg CWO per mL solution) (N = 5). After 24 hours of incubation, 10 μL of the MTT 
reagent was added to each well, and further incubated for additional 4 hours. Afterwards, 
formazan crystals were dissolved by adding 150 μL of a 10% w/v SDS solution to each well, and 
the absorbances at 570 nm were immediately measured using a microplate reader (BIO-RAD 
Microplate Reader-550). The wells with no cells, i.e., containing only the DMEM growth 
medium, the nanoparticles, and the MTT reagent, were used as the blanks. The wells containing 
cells (that had not been treated with the nanoparticles) in the medium with the MTT reagent were 
used as controls. 
2.8 Clonogenic cell survival assay 
HN31cells were seeded in 60-mm culture dishes at densities of 0.2 × 10
3
 cells per dish 
for 0 Gy, 1.0 × 10
3
 cells per dish for 3 Gy, 2.0 × 10
3
 cells per dish for 6 Gy, and 5.0 × 10
3
 cells 
per dish for 9 Gy radiation dose. Samples were prepared in quadruplet for each radiation dose (N 
= 4). Three groups were tested: (1) cells treated for 3 hours with PEG-PLA-coated CWO NPs, 
(2) cells treated for 3 hours with PTX-loaded PEG-PLA-coated CWO NPs, and (3) untreated 
cells (control). After 3 hours of nanoparticle treatment, cells were exposed to various doses of 
320 keV X-rays at a dose rate of 2.15 Gy per minute (XRAD 320, Precision X-Ray). Irradiated 
cells were cultured for 14 days (in order to make sure that clonogenically active cells undergo at 
least 6 generations of cell division). Colonies resulting from radio-resistant cells were stained 
with Crystal Violet. Colonies of more than 50 daughter cells in culture were counted (N = 4). 
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The Plating Efficiency (PE) and the Survival Fraction (SF) were calculated based on the number 
of such colonies relative to that of the respective non-irradiated subgroup for each group: PE (%) 
= (number of colonies survived) / (number of cells initially plated) × 100; SF (%) = (PE of a 
treated group) / (PE of control) × 100. Survival fraction (SF) vs. radiation dose (D) data were fit 
to the linear quadratic model, SF(D) = exp[-(αD+βD2)], where α and β are fit parameters. The 
Sensitization Enhancement Ratio (SER) was calculated as the ratio of the X-ray dose needed to 
obtain 10% survival in untreated cells relative to the dose needed to obtain 10% survival in 
nanoparticle-treated cells. 
2.9 HN31 tumor xenografts in NRG mice 
Animal studies were performed in accordance with the guidelines of the American 
Association for Accreditation of Laboratory Animal Care (AAALAC). Immune-deficient Non-
Obese Diabetic (NOD) Rag Gamma (NRG) mice (6 – 7 weeks old, female) were housed in 
standard cages within a pathogen-free facility with free access to food and water and an 
automatic 12-h light-dark cycle. Mice were initially acclimated to the environment for 1 week 
prior to xenograft implantation. Subcutaneous Head and Neck Squamous Cell Carcinoma 
(HNSCC) xenografts were produced by implanting 1 × 10
6
 HN31 cells in 0.1 mL (total volume) 
of serum-free medium containing 50% Matrigel (BD Bioscience) into the mouse flanks (on Day 
0). 
2.10 Evaluation of antitumor efficacy in mouse HNSCC models 
Three samples (including the candidate formulations and control) were investigated: (i) 
PEG-PLA/CWO NPs, (ii) PEG-PLA/CWO/PTX NPs (both in sterile PBS solution), and (iii) 
blank PBS without NPs (negative control). The efficacy of these formulations was assessed 
following intratumoral (IT) administration in mouse HN31 xenografts (NRG mice, N = 8) both 
in the presence and absence of X-ray irradiation. HN31 xenografts were prepared as described 
above. Once the tumor size reached the 100 – 150 mm3 level, NP formulations (total 100 – 150 
μL solution containing 10 mg/mL of CaWO4) were IT administered in two portions over two 
days (on Day 0 and Day 1) to a final NP concentration of 10 mg CWO per cc tumor; this NP 
dose level was adopted based on recent clinical studies by Nanobiotix that tested safety and 
efficacy of intratumorally delivered HfO2 NP radio-sensitizers [44]. NP-treated tumors were 
exposed to total 8 Gy fractionated X-Ray doses (with a daily fraction of 2 Gy repeated over 4 
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consecutive days, t = 1 – 4 days). The tumor sizes were measured using a digital caliper at 
regular intervals. The tumor volume was calculated by the formula, V = (π/6)LWH where L, W 
and H are the length, width and height of the tumor, respectively. Mouse survival analysis was 
performed using the standard ICH (The International Council for Harmonisation of Technical 
Requirements for Pharmaceuticals for Human Use) criteria (euthanasia is required if tumor size 
> 2000 cc or body weight reduction > 20%). Following euthanization, tumor tissues were 
collected and wet weighed. Tumor and organ (liver, spleen, lung, heart, kidney, and brain) 
specimens were also collected for histology analysis. 
2.11 Evaluation of NP biodistribution (BD) in mouse HNSCC models 
The BD of CWO NPs were investigated in HN31 xenograft-bearing NRG mice (3 mice 
per treatment group; see Section 2.9 above) following IT administration of PEG-PLA/CWO/PTX 
NPs (N = 3). The time-dependent CWO concentrations in tumor, blood and other selected tissues 
were measured by atomic absorption spectroscopy (AAS) as previously described [36]. The 
following specific procedures were used. Total 21 mice were divided into 7 groups (Groups I – 
VII) with 3 mice per group. Mice in Groups I – VI received IT injections of PEG-
PLA/CWO/PTX NPs at Days 0 and 1 (as described in Section 2.10), whereas mice in Group VII 
received only PBS via IT route at Days 0 and 1 (control). NP/PBS-injected mice were treated 
with 2 Gy daily fractions of 320 keV X-rays during first 4 days (i.e., at Days 1, 2, 3 and 4, up to 
total 8 Gy X-ray dose). Groups I, II, III, IV, V and VI was sacrificed by euthanization at Day 1, 
3, 5, 7, 14 and 30, respectively. The cumulative X-Ray doses mice received were 2 Gy for Group 
I, 4 Gy for Group II, and 8 Gy for all other Groups (III – VI). Control mice (Group VII) were 
euthanized at Day 1. Tumor and organ (liver, spleen, kidneys, lungs, brain, and heart) were 
collected after euthanization. Tissue samples were processed for AAS analysis using the 
published procedure[36]. 
2.12 Statistical analysis 
All in vitro measurements were performed in minimum triplicates. Different animal 
numbers were chosen for different in vivo assays based on our experience and needs in terms of 
statistical significance. All data are presented as mean ± standard deviation. A one-way ANOVA 
was used to determine whether there was a statistically significant difference in effect between 
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different treatment groups for data presented in Figures 4, 5 and 6. Kaplan-Meier survival 
analysis was used to plot unadjusted survival of mice treated with different formulations; results 
(Figure 7) were analyzed using the log-rank test. Difference was considered statistically 
significant if p < 0.05 (*) and highly significant if p < 0.01 (**). 
 
3. RESULTS & DISCUSSION 
3.1  Paclitaxel release kinetics 
 
As explained in Scheme 1, CWO NPs are coated with PEG-PLA polymers. Hydrophobic 
PLA chains form a globular domain wherein CWO NPs are encapsulated. Hydrophilic PEG 
chains form a hydrated brush layer. Water-insoluble PTX molecules are co-encapsulated within 
the hydrophobic PLA domain. The amount of PTX released from PEG-PLA-coated CWO NPs 
was measured by HPLC for 32 days; both X-ray-irradiated and non-irradiated samples were 
tested. As control, PTX release from PEG-PLA micelles (containing no co-encapsulated CWO 
NPs) was also quantitated. Notably, it was discovered that in the absence of radiation, PEG-
PLA/CWO/PTX NPs showed the lowest PTX release; about 75% PTX remained unreleased at 
Day 32 (Figure 2(A)). In contrast, upon exposure to 7 Gy X-Ray dose, a sudden rapid release of 
PTX was observed (that is, close to 70% of the initially loaded PTX amount was released within 
3 days following X-ray irradiation); this radiation-triggered rapid release phase was followed by 
a slower release phase over the remaining non-irradiated period (Figure 2(A)). At the end of the 
30-day period following radiation, a total of about 90% of the loaded PTX was released. In 
contrast, in the PTX-loaded PEG-PLA micelle case (involving no co-encapsulated CWO NPs), 
the PTX release profile was significantly less affected by X-ray irradiation (Figure 2(B)). These 
results indicate that the process of radiation-triggered PTX release from PEG-PLA/CWO/PTX 
NPs is enabled by the co-encapsulation of CWO NPs. Figure S4 displays a comparison of PTX 
release profiles between non-irradiated PTX-loaded PEG-PLA micelles in the presence and 
absence of co-encapsulated CWO NPs (redrawn from Figures 2(A) and 2(B)). These data 
suggest that when co-encapsulated with CWO NPs, PTX molecules are encapsulated into the 
deeper region of the PLA layer. However, PTX is rapidly released upon X-ray irradiation (Figure 
2(A)) because of PLA degradation under X-ray irradiation (Section 3.2). 
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The PTX release rate was found to be proportional to radiation dose. As shown in Figure 
2(A), when a lower X-Ray dose (2 Gy) was used, the slope of the PTX release profile in the 
rapid release phase was proportionally decreased; in the 2 Gy case, a little over 30% of the 
initially loaded PTX amount was released within 3 days following X-ray irradiation. At the end 
of the 30-day period post radiation, a total of close to 40% of the loaded PTX was released. 
 
 
 
Figure 2. (A) Cumulative PTX release profiles for X-ray-irradiated vs. non-X-ray-irradiated PEG-PLA/CWO/PTX 
NPs over 32 days. NPs were irradiated with a single 7 or 2 Gy dose of 320 keV X-rays at Day 2. Over 50% PTX 
release occurred during Days 2 – 4 following X-ray irradiation. (B) Cumulative PTX release profiles for X-ray-
irradiated vs. non-X-ray-irradiated PEG-PLA micelles loaded with PTX (with no co-encapsulated CWO NPs) over 
33 days. The PTX-loaded PEG-PLA micelles were irradiated with a single 7 Gy dose of 320 keV X-rays at Day 2. 
X-ray irradiation only had a small influence on PTX release from PEG-PLA micelles. 
 
3.2 Photo-lytic degradation of PLA 
Under X-ray irradiation, UV-A is generated by CWO NPs. Radiation causes the release 
of PTX from the PLA coating layer into the aqueous surrounding (Figure 2(A)). We believe that 
this PTX release triggered by X-rays is due to the degradation of the PLA polymer that occurs 
under X-ray irradiation. In order to confirm the degradation of PLA under X-ray irradiation, 
GPC measurement was performed on the PEG-PLA re-extracted with chloroform from PEG-
PLA-coated CWO NPs following exposure to X-rays (320 keV, 7 Gy) (“PEG-PLA/CWO + X-
Ray”) (Figure 3). In Figure 3, a GPC trace for pristine PEG-PLA (“PEG-PLA”) is also displayed 
for comparison. Also of note, no difference in GPC curves was observed between pristine PEG-
PLA and the PEG-PLA re-extracted from non-X-ray-exposed PEG-PLA-coated CWO NPs (data 
not shown). As shown in the figure, the X-ray-exposed sample (“PEG-PLA/CWO + X-ray”) 
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showed an overall shift of the peak to, and a shoulder developed, at longer elution times (on the 
lower molecular weight side), which clearly indicates that the degradation of the polymer 
occurred; the PTX release triggered by X-ray radiation is due to the chemical degradation of the 
encapsulating polymer (not due to physical excitation processes). 
It should be noted that data shown in Figure 2(B) suggest that X-rays alone may also 
cause slight chemical change in PLA. It has been reported in the literature that short wavelength 
UV light (100 – 280 nm UV-C, and 280 – 320 nm UV-B) can directly cause degradation of PLA 
[45-48]. However, it is a reasonable question whether the secondary UV-A light generated by 
CWO NPs under X-ray irradiation by itself (having a peak wavelength of about 400 nm) can 
effectively cause polymer degradation, particularly at the low UV-A dose level produced by 7 
Gy of 320 keV X-ray radiation (≈ 0.561 J/cm2) [49]. Yet another possible mechanism is that 
CWO plays a catalytic role in the X-ray-induced PLA degradation process. It has been known 
that CWO has photo-catalytic activity under UV-A light; under the influence of UV-A light, 
CWO catalyzes the degradation of water and oxygen molecules in the surrounding environment 
[50]. However, CWO-mediated photo-catalytic degradation of PLA has not previously been 
demonstrated. To better understand the exact mechanism of the PLA degradation in X-ray-
irradiated PEG-PLA/CWO NPs, additional GPC measurements were made on (i) PEG-PLA re-
extracted from PEG-PLA-coated CWO NPs following exposure to direct UV-A light (365 nm, 
2.8 J/cm
2
, equivalent 365 nm UV-A fluence generated by PEG-PLA/CWO NPs under 7 Gy 320 
keV X-ray radiation) (“PEG-PLA/CWO + UV-A”), (ii) PEG-PLA re-extracted from empty (non-
CWO-loaded) PEG-PLA micelles following exposure to X-rays (320 keV, 7 Gy) (“PEG-PLA + 
X-Ray”), and (iii) PEG-PLA re-extracted from empty (non-CWO-loaded) PEG-PLA micelles 
following exposure to direct UV-A light (365 nm, 2.8 J/cm
2) (“PEG-PLA + UV-A”). The results 
are also presented in Figure 3. As shown in the figure, both X-rays alone (“PEG-PLA + X-Ray”) 
and UV-A light alone (“PEG-PLA + UV-A”) caused PLA degradation even in the absence of 
CWO NPs. Further, the extents of PLA degradation were comparable between “PEG-PLA + 
UV-A” and “PEG-PLA/CWO + UV-A”, and also between “PEG-PLA + X-Ray” and “PEG-
PLA/CWO + X-Ray”. These results indicate that CWO does not produce any significant 
catalytic activity for PLA degradation; the PLA degradation is therefore not of photo-catalytic 
type, but it is a photo-lysis reaction. We speculate that this PLA degradation reaction is 
essentially a hydrolysis process. Although insoluble in water, PLA is known to absorb water up 
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to about 1% by weight [51]. UV-A/X-ray radiation generates reactive oxygen species (such as 
hydroxyl radicals) via UV-A/radiolysis of water [52, 53], which reacts with and cleaves the ester 
bonds in PLA. 
Based on the results presented in this and previous sections, we speculate more 
specifically that the mechanism of radiation-induced PTX release involves two processes: (i) 
partitioning/accumulation of PTX in the vicinity of the CaWO4 core (causing very slow release 
of PTX in the absence of radiation) (Figure 2(A)), and (ii) photo-lytic degradation of PLA 
(triggering rapid PTX release under X-ray irradiation) (Figure 3). Regarding (i), we believe that 
the poor water solubility of PTX (≈ 0.1 – 0.3 µg/ml) [54] is the key parameter contributing to the 
accumulation of PTX in the deeper region of the PLA domain; because of its poor water 
solubility, PTX precipitates to the CaWO4 surface earlier than did PLA during the solvent 
exchange process. Therefore, similar chemotherapeutic formulations are possible with other 
types of chemo drugs, as long as the drug is similarly poorly water-soluble. Further study is 
needed to test this possibility. 
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Figure 3. GPC traces of (1) pristine PEG-PLA (“PEG-PLA”), (2) PEG-PLA re-extracted from PEG-PLA-coated 
CWO NPs following exposure to X-rays (320 keV, 7 Gy) (“PEG-PLA/CWO + X-Ray”), (3) PEG-PLA re-extracted 
from PEG-PLA-coated CWO NPs following exposure to direct UV-A light (365 nm, 2.8 J/cm
2
 (of note this UV-A 
fluence used is significantly higher than the equivalent 365 nm UV-A fluence generated by PEG-PLA/CWO NPs 
under 7 Gy 320 keV X-ray radiation (≈ 0.561 J/cm2 [49]))) (“PEG-PLA/CWO + UV-A”), (4) PEG-PLA re-extracted 
from empty (non-CWO-loaded) PEG- LA micelles following exposure to X-rays (320 keV, 7 Gy) (“PEG-PLA + X-
Ray”), and (5) PEG-PLA re-extracted from empty (non-CWO-loaded) PEG-PLA micelles following exposure to 
direct UV-A light (365 nm, 2.8 J/cm
2
) (“PEG-PLA + UV-A”). 
 
3.3 Non-cytotoxicity of PEG-PLA CWO NPs 
In vitro cytotoxicities of uncoated CWO NPs (10 nm diameter) and PEG-PLA-
encapsulated CWO NPs (50 nm hydrodynamic diameter) were evaluated in HN31 (p53-mutant 
human head and neck cancer) cells using the standard MTT protocol at various CWO 
concentrations ranging from 0.16 to 5 mg/ml. The results are presented in Figure 4. As shown in 
the figure, no significant toxicity was observed for both samples up to a nominal CWO 
concentration of about 1.25 mg/ml. At higher concentrations (2.5 and 5 mg/ml), a slight 
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reduction (10 – 20%) in viability was observed. It should be noted that the actual CWO 
concentration that the cells experience is typically significantly higher than the nominal value of 
CWO concentration because of the sedimentation of the CWO NPs that occurred during the 24-h 
incubation period. The nominal NP concentration value of, for instance,1.25 mg of CWO per ml 
of solution used in the cell culture study is equivalent to total 50 ng of CWO per HN31 cell (0.20 
ml of medium used per well having a surface area of 32 mm
2
 and a cell confluence of 156 
cells/mm
2
). The time it takes for a PEG-PLA/CWO/PTX NP (of 66 nm hydrodynamic diameter) 
to sediment a distance of 0.625 cm (the height of the cell culture medium in our study) is 
estimated to be about 51.8 days, using the equation, τ ≈ 9lη/(2R2Δρg), where τ is the 
sedimentation time, l is the sedimentation distance, η is the viscosity of the medium (water), R is 
the radius of the NP, Δρ is the density difference between the NP and medium, and g is the 
gravitational acceleration constant. Therefore, we expect that by the end of the 24-hour 
incubation period, about 1.9% of the NPs in the system have sedimented to the bottom of the 
well, which gives an estimate of 0.97 ng of CWO per HN31 cell for the actual CWO 
concentration that the cells experience at the bottom of the plate. As explained in Section 2.10, 
the NP dose level used in our in vivo study (results to be discussed in Section 3.5) was 10 mg of 
CWO compound per cc of tumor. Assuming an HN31 cell density of 10
9
 cells per cc of tumor 
for mouse HN31 xenograft tissue [55], the NP concentration used in our in vivo study (10 mg of 
CWO per cc of tumor) is converted to a value of 0.010 ng of CWO per HN31 cell, which is 
about two orders of magnitude lower than the cytotoxicity threshold estimated by the in vitro 
method (0.97 ng of CWO per cell).  
Therefore, the results presented in Figure 4 clearly support that CWO NPs, regardless of 
whether PEG-PLA-coated or uncoated, are completely non-cytotoxic at therapeutically relevant 
NP doses. 
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Figure 4. In vitro cytotoxicities of (A) uncoated CWO NPs (10 nm diameter) and (B) PEG-PLA-coated CWO NPs 
(50 nm hydrodynamic diameter) in HN31 cells assessed by the MTT method (N = 5). HN31 cells were seeded on 
96-well culture plates at a density of 0.5 × 10
4
 cells per well and incubated for 24 hours prior to exposure to 
nanoparticles. The MTT measurements were performed at 24 h post nanoparticle treatment. The p-values for all 
pairs of groups are summarized in Table 1 below. 
 
Table 1. Results of the statistical analysis of—that is, p-values for—the tumor growth data presented in Figures 
4(A) (upper table) and 4(B) (lower table) (N = 5). 
CWO Concentration (mg/mL) 0.16 0.31 0.63 1.25 2.5 5.0 
0 0.384 0.157 0.194 0.223 0.006 0.002 
0.16 - 0.378 0.378 0.523 0.025 0.006 
0.31 - - 0.867 0.813 0.22 0.058 
0.63 - - - 0.714 0.402 0.139 
1.25 - - - - 0.147 0.041 
2.5 - - - - - 0.151 
 
CWO Concentration (mg/mL) 0.16 0.31 0.63 1.25 2.5 5.0 
0 0.505 0.478 0.227 0.051 0.045 0.029 
0.16 - 0.918 0.558 0.12 0.11 0.049 
0.31 - - 0.677 0.191 0.173 0.083 
0.63 - - - 0.171 0.157 0.053 
1.25 - - - - 0.742 0.137 
2.5 - - - - - 0.292 
 
 
3.4 Clonogenic survival following various doses of radiation in HN31 cells treated with 
concurrent PEG-PLA/CWO/PTX NPs 
An in vitro clonogenic study was performed to determine whether PEG-PLA/CWO/PTX 
NPs are indeed capable of inducing a significant enhancement of the tumor suppressive effect of 
X-rays/γ rays beyond what is achievable with PEG-PLA/CWO NPs (i.e., without co-delivered 
PTX). Again, the HN31 cell line was used for this investigation. As shown in Figure 5, 
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concomitant PEG-PLA/CWO/PTX NPs produced a significantly greater radiation sensitization 
effect than concomitant PEG-PLA/CWO NPs. The values of the Sensitizer Enhancement Ratio 
or SER (defined as the ratio of the radiation dose at 10% clonogenic survival in the absence of 
nanoparticles relative to the radiation dose at 10% survival in the presence of nanoparticles) were 
estimated to be 1.16 for concomitant PEG-PLA/CWO NPs (i.e., without PTX) and 1.45 for PEG-
PLA/CWO/PTX NPs (with co-encapsulated PTX). 
 
Figure 5. Effect of X-ray irradiation on clonogenic survival of HN31 cells at various X-ray doses. HN31 cells were 
irradiated in the presence of PEG-PLA/CWO/PTX NPs (CWO concentration = 0.20 mg/ml, PTX concentration = 
0.023 mg/ml, PEG-PLA:CWO:PTX = 1.3:1.0:0.12 by weight (determined by AAS, HPLC and TGA)) or PEG-
PLA/CWO NPs (CWO concentration = 0.20 mg/ml, PEG-PLA:CWO = 1.3:1.0 by weight (determined by AAS and 
TGA [35])). HN31 cells were seeded on 60 mm culture plates at densities 0.2 × 10
3
 (0 Gy), 1.0 × 10
3
 (3 Gy), 2.0 × 
10
3
 (6 Gy) and 5.0 × 10
3
 (9 Gy) cells per plate. After 24 h incubation with nanoparticles, cells were exposed to 
various doses of 320 keV X-ray radiation. All doses were given in single fractions. Irradiated cells were cultured for 
14 days. Colonies resulting from radio-resistant cells were stained by Crystal Violet. Colonies of more than 50 
daughter cells in culture were counted (N = 4). Table 2 below summarizes the linear quadratic fit results and the 
SER (Sensitization Enhancement Ratio estimated at 10% clonogenic survival) values. The p-values for all pairs of 
groups are summarized in Table 3. 
Table 2. Summary of the results of the analysis of the data shown in Figure 4. α and β are the linear-quadratic 
exponential fit parameters. The Sensitization Enhancement Ratio or SER is defined as the ratio of the radiation dose 
at 10% clonogenic survival in the absence of CWO relative to the radiation dose at 10% survival in the presence of 
CWO. 
  α β α/β    SER 
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Control 0.159 0.044 3.61  1 
PEG-PLA/ CWO NP 0.266 0.039 6.82 1.15 
PEG-PLA-PTX/CWO 
NP 0.436 0.036 12.11 1.40 
 
Table 3. Results of the statistical analysis of—that is, p-values for—the tumor growth data presented in Figure 5 (N 
= 4). 
Radiation Dose (Gy) Formulation PEG-PLA/CWO NP PEG-PLA/CWO/PTX NP  
3 
Control 0.191 0.006 
PEG-PLA/CWO NP - 0.0012 
6 
Control 0.02 0.0012 
PEG-PLA/CWO NP - 0.0052 
9 
Control 0.716 0.599 
PEG-PLA/CWO NP - 0.44 
 
The clonogenic survival curves for radiated HN31 cells (regardless of whether X-rays 
were used alone or in combination with concomitant PEG-PLA/CWO/PTX or PEG-PLA/CWO 
NPs) were seen to follow the standard exponential-quadratic decay formula: 
SF(D) = exp[-(αD + βD2)]    (1) 
where SF is the survival fraction, D is the X-ray dose, and α and β are adjustable parameters for 
fitting data to the model. Best fit curves are shown as solid curves in Figure 5, and fitting results 
are summarized in Table 2. It is notable in Figure 5 and Table 2 that even in the absence of co-
encapsulated PTX, PEG-PLA/CWO NPs were able to induce a significant enhancement of the 
tumor-suppressive effect of X-rays (SER ≈ 1.15); this result is consistent with previous data 
obtained with PEG-PLA/CWO NPs with slightly larger diameter (170 nm hydrodynamic 
diameter) under identical radiation conditions (SER ≈ 1.10) [40]. The incorporation of PTX in 
the NP formulation further significantly increased the effect of radiation (SER ≈ 1.40, Figure 5 
and Table 2). The α/β ratio also has a useful meaning; this ratio represents a radiation dose at 
which the exponential-linear cell kill effect becomes equivalent in magnitude to the exponential-
quadratic cell kill effect of radiation (at D < α/β the exponential-linear effect is dominant, 
whereas at D > α/β the exponential-quadratic effect takes over (the surviving fraction drops more 
rapidly)). It is generally known that [56]: 
 Cells that respond to radiation early have high α/β ratios; cell kill linearly increases at low 
radiation doses. The average value of α/β for early responding cells is about 10; 
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 Cells that respond late have low α/β ratios; cell kill is less at low doses, and it greatly 
increases at high doses. The average value of α/β for late responding cells is about 3; 
 Most tumor cells have high α/β ratios (equal to or greater than 10). However, some tumor 
types exhibit much lower ratios; for instance, prostate and melanoma/sarcoma typically 
show α/β values around 3 and 1, respectively. Tumors with low α/β ratios are resistant to 
low doses of radiation. 
Therefore, if chemo drug addition to radiotherapy increases the SER, while it does not affect the 
α/β ratio, chemotherapy can be said to have simply produced an additive therapeutic effect. 
However, if both the SER and the α/β ratio are increased, the cells have become more sensitive 
to low doses of radiation [56]. As shown in Table 2, concomitant PEG-PLA/CWO/PTX NPs 
significantly increased the value of the α/β ratio (α/β ≈ 12.11) relative to non-nanoparticle-treated 
control (α/β ≈ 3.61), which suggests that the PEG-PLA/CWO/PTX treatment enhanced the radio 
responsiveness of HN31 cells at low X-ray doses. Therefore, it can be deduced that PTX released 
from nanoparticles under X-ray irradiation contributed to overall cell kill by increasing 
radiotherapy efficacy (i.e., by radio sensitization) in addition to functioning as chemotherapy. It 
should also be noted that, though lesser in degree than PEG-PLA/CWO/PTX NPs, non-PTX-
loaded PEG-PLA/CWO NPs also increased both SER and α/β, which supports that PEG-
PLA/CWO NPs themselves are also an effective radio-sensitizer [40]. This means, by using PEG-
PLA/CWO/PTX NPs, an improved therapeutic effect can be achieved with the same amount of 
radiation or the same therapeutic effect can be achieved with significantly less radiation. 
 
3.5 Therapeutic efficacy of PEG-PLA/CWO/PTX NPs in mouse HN31 xenografts: Tumor 
growth, and mouse survival 
The therapeutic efficacy of intratumorally administered PEG-PLA/CWO/PTX NPs was 
evaluated in HN31 mouse xenografts in vivo. For these studies, mice were treated via 
intratumoral injection with either PTX-loaded (“PEG-PLA/CWO/PTX”) NPs, non-PTX-loaded 
(“PEG-PLA/CWO”) NPs or NP vehicle (PBS). Each treatment/control group was divided into 
two subgroups; one subgroup was treated with a sub-therapeutic dose of X-rays (320 keV, total 8 
Gy, 4 fractions of 2 Gy given one fraction per day), and the other was not given X-rays. Tumor 
growth and mouse survival were measured over time. The results are summarized in Figures 6 
(tumor growth) and 7 (mouse survival). 
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Figure 6. Tumor growth in mice treated with concomitant radiation plus PEG-PLA/CWO/PTX NPs. NRG mice (6 – 
8 weeks old, female, N = 8 per group) were implanted with HN31 cells at Day -5. Tumors were grown to 0.10 to 
0.15 cc until Day 0. Nanoparticles were intratumorally administered in 2 portions at Days 0 and 1 (total 10 mg of 
CWO per cc of tumor, and total 1.2 mg of PTX per cc of tumor; PEG-PLA:CWO:PTX = 1.3:1.0:0.12 by weight 
(determined by AAS, HPLC and TGA)). Tumors were irradiated with 320 keV X-rays (total dose 8 Gy) in 2 Gy/day 
fractions over 4 days (at Days 1, 2, 3 and 4). Control group was treated with sterile PBS. For all treatment types 
(PEG-PLA/CWO/PTX, PEG-PLA/CWO, and Control), non-X-ray-treated animals were also included in the study 
for comparison. For each group tumor size data are shown up to the time point at which any one mouse died or was 
sacrificed because of tumor overgrowth (> 2000 mm
3
) or excessive mouse weight loss (> 20%). The same criteria 
were used for the survival analysis shown in Figure 7. Error bars represent standard deviations. The p-values for all 
pairs of groups are summarized in Table 4 below. 
Table 4. Results of the statistical analysis of—that is, p-values for—the tumor growth data presented in Figure 6 (N 
= 8). 
 
PBS 
PEG-
PLA/CWO 
PEG-
PLA/CWO/PTX 
PBS + 
X-Ray 
PEG-
PLA/CWO + 
X-Ray 
PEG-
PLA/CWO/PTX + 
X-Ray 
PBS - 0.023 0.022 0.007 0.007 0.005 
PEG-PLA/CWO - - 0.023 0.008 0.008 0.006 
PEG-
PLA/CWO/PTX - - - 0.007 0.007 0.005 
PBS + X-Ray - - - - 0.0002 0.0001 
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PEG-PLA/CWO + 
X-Ray - - - - - 0.0001 
 
 
Figure 7. Kaplan-Meier curves for survival of mice (N = 8) treated with PEG-PLA/CWO/PTX NPs, PEG-
PLA/CWO NPs, and PBS (control) with and without X-rays. PBS solutions of NPs were injected into HN31 
xenografts (0.10 – 0.15 cc) in NRG mice to a final NP concentration of 10 mg of CWO per cc of tumor and a final 
PTX concentration of 1.2 mg of PTX per cc of tumor (PEG-PLA:CWO:PTX = 1.3:1.0:0.12 by weight (determined 
by AAS, HPLC and TGA)). A total radiation dose of 8 Gy was given in 4 fractions of 2 Gy per fraction, one fraction 
per day over 4 days (at t = 1, 2, 3 and 4 days) following NP administration (at t = 0 and 1 day). Mice were 
euthanized based on the standard ICH criteria: (a) tumor volume > 2.0 cc; (b) body weight loss > 20% of the original 
body weight. Analysis of survival data was performed using the log-rank test. Values of p < 0.05 were considered 
statistically significant. The PEG-PLA/CWO/PTX + X-Ray group (blue solid line) and PEG-PLA/CWO + X-Ray 
group (black solid line) were significantly different from the Control (PBS with no X-Ray) group and also from the 
NPs with no X-Ray groups (p < 0.05 for each pair-wise comparison). The p-values for all pairs of groups are 
summarized in Table 5. The median survival times were: 18 days for “PBS”, 22 days for “PEG-PLA/CWO”, 22 
days for “PEG-PLA/CWO/PTX”, 28 days for “PBS + X-Ray”, 37 days for “PEG-PLA/CWO + X-Ray”, and 45 days 
for “PEG-PLA/CWO/PTX + X-Ray”. 
Table 5. Results of the statistical analysis of—that is, p-values for—the mouse survival data presented in Figure 7 
(N = 8). 
 
PBS 
PEG-
PLA/CWO 
PEG-
PLA/CWO/PTX 
PBS + 
X-Ray 
PEG-
PLA/CWO + 
X-Ray 
PEG-
PLA/CWO/PTX + 
X-Ray 
PBS - 0.344 0.622 0.119 0.008 0.00002 
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PEG-PLA/CWO - - 0.554 0.284 0.04 0.00005 
PEG-
PLA/CWO/PTX - - - 0.255 0.029 0.0001 
PBS + X-Ray - - - - 0.045 0.0007 
PEG-PLA/CWO + 
X-Ray - - - - - 0.00008 
 
As shown in Figure 6, 8 Gy radiation caused a significant decrease in tumor growth, 
which is obvious, for instance, from comparison of the “PBS + X-Ray” data to the “PBS” data. 
Most importantly, a concomitant treatment with PEG-PLA/CWO/PTX NPs produced a 
significant enhancement of the tumor suppressive effect of X-rays (Figure 6).  As shown in 
Figure 7, even without PTX, X-rays with concomitant PEG-PLA/CWO NPs caused a significant 
increase in survival time relative to X-ray radiation only, because of the CWO’s radio-
sensitization effect  [40] even though the synergistic effect of radiation and PEG-
PLA/CWO/PTX was not immediately visible in the tumor size study (Figure 6). PEG-
PLA/CWO/PTX NPs plus X-rays further increased the mouse survival by about 10 days relative 
to the “PEG-PLA/CWO + X-Ray” treatment. Log-rank analysis confirmed that the survival 
benefit produced by “PEG-PLA/CWO/PTX + X-Ray” is statistically significant relative to any 
other treatment: “PEG-PLA/CWO + X-Ray” (p = 0.00008), “PBS + X-Ray” (p = 0.0007), “PEG-
PLA/CWO/PTX” (p = 0.0001), “PEG-PLA/CWO” (p = 0.00005), and “PBS” (p = 0.00002). It 
should be noted that in the absence of radiation, “PEG-PLA/CWO/PTX” behaved 
indistinguishably to “PEG-PLA/CWO” (Figure 7), which is consistent with the data shown in 
Figure 2(A) (which showed that PTX release from “PEG-PLA/CWO/PTX” is minimal in the 
absence of X-rays). Overall, these results clearly support the therapeutic potential of the 
concurrent X-ray and “PEG-PLA/CWO/PTX” therapy. 
The results presented in Figures 6 and 7 strongly support that PEG-PLA/CWO/PTX NPs 
will produce significant effects of enhancing radiation effect and prolonging survival when using 
clinically relevant doses of radiation (i.e., 30 – 40 fractions of 2 – 3 Gy daily X-ray dose). In the 
present study, a sub-therapeutic radiation dose (4 fractions of 2 Gy per fraction given one 
fraction per day) was used in order to make the study in a mouse HN31 xenograft model 
manageable in terms of experiment timescale (less than a few months). However, data obtained 
using 4 × 2 Gy radiation (Figures 6 and 7), in fact, allow us to predict what will happen when 
usual clinical doses of radiation are used (as discussed below). 
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Let us first discuss whether in vivo data shown in Figure 7 are predictable from in vitro 
data shown in Figure 5. Using the linear-quadratic model parameters (α and β) obtained from 
clonogenic assay results shown in Figure 5, we can predict values of survival fraction (SF) for 
HN31 cells irradiated with 8 Gy in 4 fractions; that is, SF(D = 8 Gy in 4 fractions) ≈ [SF(D = 2 
Gy in single fraction)]
4
, assuming that the time interval between radiation fractions (1 day) was 
sufficient for cell’s recovery from sub-lethal radiation damage [57]. The resulting predicted 
values were: SF(D = 8 Gy in 4 fractions) ≈ 0.138 for “Control”, 0.0638 for “PEG-PLA/CWO”, 
and 0.0172  for “PEG-PLA/CWO/PTX” (notations same as in Figure 5). In in vivo studies 
presented in Figures 6 and 7, HN31 xenografts were treated with X-rays when the tumor volume 
reached a level of about 150 mm
3
 (containing an estimated amount of about 1.5 × 10
8
 cells 
assuming a cell density of 10
9
 cells per cc of tumor [55]). Therefore, in our in vivo studies, the 
number of clonogenically active cells within the tumor immediately following 4 fractions of 2 
Gy radiation (at Day 4 in Figure 6) is estimated to be: 2.08 × 10
7
 cells for “PBS + X-Ray”, 9.57 
× 10
6
 cells for “PEG-PLA/CWO + X-Ray”, and 2.58 × 106 cells for “PEG-PLA/CWO/PTX + X-
Ray”. Separately, from Figure 6 (i.e., from the slope of the tumor growth curve for “PBS” 
between Days 4 and 12 in Figure 6), the doubling time of HN31 cells in mouse xenografts in 
vivo is estimated to be about 5.09 days. Now, using these information, the time it takes for the 
irradiated tumor to re-grow to a size of 2.0 cc (which is the tumor volume limit used as a 
euthanasia criterion in our vivo studies) post 4 × 2 Gy radiation is estimated to be: 34 days post 
radiation for “PBS + X-Ray”, 40 days post radiation for “PEG-PLA/CWO + X-Ray”, and 49 
days post radiation for “PEG-PLA/CWO/PTX + X-Ray”. These predicted values of mouse 
survival time are very close to experimental values: as stated in the figure caption for Figure 7, 
the median mouse survival times were measured to be 28 days post first NP administration (24 
days post radiation) for “PBS + X-Ray”, 37 days post first NP administration (33 days post 
radiation) for “PEG-PLA/CWO + X-Ray”, and 45 days post first NP administration (41 days 
post radiation) for “PEG-PLA/CWO/PTX + X-Ray”. Given the simplicity of the model used in 
the calculation and also other euthanasia criteria used in experiment (e.g., > 20% weight loss), 
this agreement is quite surprising. Nevertheless, this analysis validates the consistency of data 
presented in Figures 5, 6 and 7. 
Using the above SF model, now we can further predict mouse survival times under dose 
conditions close to clinical practice. For instance, if 20 fractions of 2 Gy per fraction are used, 
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the survival fractions of HN31 cells are predicted to be: SF(D = 40 Gy in 20 fractions) ≈ 5.12 × 
10
-5
 for “Control”, 1.06 × 10-7 for “PEG-PLA/CWO”, and 1.50 × 10-9 for “PEG-
PLA/CWO/PTX”. Using the same procedure as above, the time it takes for the irradiated tumor 
to re-grow to a size of 2.0 cc (mouse survival time) post 20 × 2 Gy radiation is estimated to be: 
92 days post radiation for “PBS + X-Ray”, 120 days post radiation for “PEG-PLA/CWO + X-
Ray”, and 168 days post radiation for “PEG-PLA/CWO/PTX + X-Ray”. Concurrent “PEG-
PLA/CWO/PTX + X-Ray” is, therefore, predicted to produce a significant survival benefit of 
about 3.5 months relative to X-rays only (“PBS + X-Ray”) or about a month even compared to 
“PEG-PLA/CWO + X-Ray”. 
We note that it is not possible at this point to draw a definitive conclusion from this study 
as to whether these nanoparticles will indeed enhance X-ray’s efficacy in treating real patients 
with spontaneous tumors under clinical radiation conditions. We are in the process of initiating a 
pilot clinical study to evaluate the efficacy of intratumorally injected PEG-PLA/CWO/PTX NP-
mediated concomitant chemo-radio combination therapy in veterninary patients with 
spontaneous tumors. 
 
3.6 Biodistribution of PEG-PLA/CWO/PTX NPs in tumor-bearing mice following 
intratumoral administration 
An ideal intratumoral NP drug carrier system would be the one that is sufficiently large to 
stay within the tumor boundary and at the same time) small enough to spread out uniformly 
throughout inside the tumor tissue. In this regards, the previous literature [58] suggests that the 
ideal NP size should be about 30 – 60 nm. The present PEG-PLA/CWO/PTX NP formulation 
was developed based on these considerations. A biodistribution (BD) study was performed to 
evaluate whether PEG-PLA/CWO/PTX NPs stay localized at the solid tumor site for the duration 
of a normal course of radiation therapy (40 – 50 days for HNSCC [37]) following intratumoral 
administration in the HN31 xenograft mouse model. A long tumor residence time of PEG-
PLA/CWO/PTX NPs (> one month) will enable a single injection of these nanopartciels at the 
beginning of treatment period to replace multiple daily/weekly injections of standard chemo 
radio-sensitizers [59]. Complete retention of NPs within the infused tumor region is also key to 
controlling the PTX availability within the tumor and minimizing systemic side effects. In this 
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study, 21 mice were divided into 7 groups of 3 mice each (6 treatment groups, and one control 
group). All mice in treatment groups received an identical treatment, i.e., an intratumoral 
injection of PEG-PLA/CWO/PTX NPs (to a final NP concentration of 10 mg CWO per cc tumor, 
injected in 2 portions at t = 0 and 1 days) following by X-ray radiation (320 keV, 4 fractions of 2 
Gy per day over 4 days, i.e., at Days 1, 2, 3 and 4); the treatment details were the same as in the 
efficacy study discussed above (Section 3.5). The control group was treated with vehicle (PBS) 
only (with no radiation therapy) and sacrificed at Day 2. Animals in different groups were 
euthanized at different time points (t): t = 2 day (Group I, exposed to 2 Gy radiation on Day 1); t 
= 4 days (Group II, exposed to 2 + 2 Gy radiation on Days 1 and 2, respectively); t = 6 days 
(Group III, exposed to 2 + 2 + 2 Gy radiation on Days 1, 2 and 3, respectively); t = 8 days 
(Group IV, exposed to 2 + 2 + 2 + 2 Gy radiation on Days 1, 2, 3 and 4, respectively); t = 16 
days (Group V, exposed to 2 + 2 + 2 + 2 Gy radiation on Days 1, 2, 3 and 4, respectively); and t 
= 31 days (Group VI, exposed to 2 + 2 + 2 + 2 Gy radiation on Days 1, 2, 3 and 4, respectively)). 
Tumor, blood and organ (brain, heart, kidney, lung, liver and spleen) samples were collected, and 
analyzed for calcium (Ca) content by atomic absorption spectroscopy (AAS) [36] (N = 3). The 
results of this BD study are presented in Figure 8. As shown in the figure, the data confirmed that 
the CWO NPs remained localized in the tumor for (at least) 31 days after injection. Over this 
one-month measurement period, intratumoral CWO NP retention was maintained at a level 
between about 70% and 90% with statistical fluctuations due to measurement uncertainties (N = 
3); note that, even at one day after the completion of NP injections (“Day 2”), the amount of 
CWO NPs detected in the tumor appears to have been significantly less than the amount injected, 
which is thought to be due to loss of the NP solution during the intratumoral injection process. 
Trace amounts of CWO NPs were occasionally detected in other organs, but these results were 
statistically insignificant (N = 3). 
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Figure 8. Time-dependent BD profiles of PEG-PLA/CWO/PTX NPs in tumor and major organs determined by 
AAS following intratumoral administration in HN31 mouse xenografts. Error bars represent standard deviations (N 
= 3). In control mice, no CWO was detected in any organs (data not shown). The “Day 0” bar graphs represent 
theoretical CWO NP BD levels that would be obtained immediately after NP injection. In some measurement groups 
(particularly, at Days 6 and 8), the sum of the percentage injected doses was greater than 100 percent because of 
errors associated with AAS measurements. Statistical analysis was performed for all organs and times relative to 
“Day 0” using one-way ANOVA. A difference is statistically significant if p < 0.05 (*). A difference is statistically 
highly significant if p < 0.005 (
**
). The p-values for all measurement groups are summarized in Table 6 below. 
 
Table 6. Results of the statistical analysis of—that is, p-values for—the CWO NP BD data presented in Figure 8 (N 
= 3). 
  Day 2 Day 4 Day 6 Day 8 Day 16 Day 31 
Brain 0.08 0.699 0.213 0.04 0.374 0.118 
Heart 0.244 0.027 0.117 0.126 1 0.021 
Kidney 0.001 0.001 0.3739 0.091 0.01 0.123 
Liver 0.273 0.228 0.318 0.259 0.347 0.122 
Lung 0.323 0.118 0.228 0.117 0.2 0.116 
Spleen 0.327 1 0.124 0.373 0.285 0.116 
Tumor 3.84E-06 0.029 0.2 0.022 7.31E-04 0.0716 
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3.7 Multi-compartmental model for predicting in vivo pharmacokinetics (PK) of 
intratumorally injected PTX 
In order to gauge the clinical benefits of using PTX-loaded PEG-PLA-encapsulated 
CWO NPs (“PEG-PLA/CWO/PTX” NPs) over conventional PTX formulations, PK modeling 
was performed using a simple multi-compartment kinetic model. Clinical PEG-PLA/CWO/PTX-
based intratumoral chemo-radio combination therapy would involve two steps: (1) intratumoral 
injection of PEG-PLA/CWO/PTX NPs, and (2) X-ray irradiation of the nanoparticle-treated 
tumor. The dynamics of intratumoral PTX concentration can be modeled with reasonable fidelity 
using a simplistic multi-compartmental PK model. Key kinetic processes involved can be 
summarized as follows. Radiation triggers the release of PTX from the polymer coating layer 
inside the tumor; in the absence of radiation, the PTX release is very slow. Released PTX will 
accumulate in the tumor compartment. On the other hand, there is continuous loss of PTX to the 
tumor exterior (e.g., by diffusion). The PTX eliminated from the tumor mainly enters the 
cardiovascular circulatory system, and eventually becomes cleared from the body through the 
kidneys [60, 61]. A diagrammatic summary of these concepts is also presented in Scheme 2 
below. 
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Scheme 2. Schematic description of the multi-compartmental pharmacokinetic model used in this study to estimate 
PTX concentrations in the PEG-PLA/CWO NPs, the tumor tissue, and the blood circulation system (denoted as Cs, 
C, and Cb, respectively) as functions of time following intratumoral administration of PEG-PLA/CWO/PTX NPs. 
In clinics, patients with locally advanced head and neck squamous cell carcinomas 
(HNSCC) typically undergo radiotherapy at a total radiation dose of 66 – 74 Gy. The protocol is 
that the total dose is distributed over a period of 40 – 50 days in 2 Gy daily fractions (5 fractions 
per week on week days with rest on weekends) [37]. PTX PK simulations were performed under 
this exact same radiation dose setting. The values of the rate constants describing the respective 
rates of PTX release from P G-PLA/CWO/PTX NPs in the absence and presence of 2 Gy X-ray 
radiation were estimated from the experimental data shown in Figure 2(A). It was assumed that 
the solid tumor had a volume of 100 cc (assumed to be invariant over time), and the tumor was 
initially injected with three different doses of PEG-PLA/CWO/PTX NPs (2, 5 or 10 mg CWO 
per cc of tumor); of note, the tumor size actually did not influence PTX PK calculations, but the 
initial nanoparticle dose level, of course, did influence PTX PK calculations. The initial PTX 
concentration in the PLA coating layer was fixed at 20% by weight for all calculations. The X-
ray dose used was 70 Gy, divided into 2 Gy daily fractions (with 5 fractions per week and rest on 
weekends as in clinical practice). The intraparticle, intratumoral and intracirculatory PTX PK 
profiles were traced for 210 days (≈ 7 months); all radiation sessions were completed by Day 47, 
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and no radiation was given in the remaining period. Previously, the tumor elimination rate 
constant for PTX intratumorally delivered to mouse MCF7 xenografts in the polymer 
encapsulated form has been reported: ke,t ≈ 0.005 h
-1
 [62]. A slightly lower tumor PTX 
elimination constant value (ke,t ≈ 0.001 h
-1
) was assumed for PEG-PLA/CWO/PTX NPs and 
PEG-PLA/PTX micelles assuming that spontaneous (human) tumors have a denser tissue 
structure. The intratumoral PTX concentration was calculated as a function of time by solving 
the following differential kinetic equation, ([rate of PTX accumulation within tumor] = [rate of 
PTX release from nanoparticles] – [rate of PTX elimination from tumor (e.g., due to diffusion to 
surrounding tissue, metabolization, etc.)]): 
  
  
  (    )           (2) 
where C is the PTX concentration within the tumor (in Molar units), Cs is the PTX concentration 
within the PLA “shell” layer (in Molar units), k is the rate constant for PTX release from the 
PLA layer (k ≈ 1.3 × 10-3 and 4.3 × 10-3 h-1, respectively, for unradiated and 2-Gy-irradiated 
situations, estimated from data shown in Figure 1(A) (i.e., from the slopes of the PTX release 
profiles at times between 2 and 3 days)), and ke,t is the rate constant for PTX elimination from 
the tumor (h
-1
) (value taken from the literature as mentioned above). Note that from the data 
shown in Figure 2(A), the rate constant for PTX release under 7 Gy radiation is estimated to be k 
≈ 1.6 × 10-2 h-1, which suggests that the radiation-triggered PTX release rate is roughly linearly 
proportional to radiation dose. The initial condition used was: C = 0 at t = 0. Cs is coupled to C 
by the mass balance: 
              ∫  (  
 
 
  )       (3) 
where Vs is the total volume of the PLA layers within the tumor, V is the volume of tumor, Cs,o = 
Cs(t = 0), and Vs,o  = Vs(t = 0); for simplicity, it was assumed that V and Vs did not change with 
time (i.e., V = 100 cc, and Vs = Vs,o at all times); note that constant Vs means that the integrity of 
the PLA layer is maintained at all times. Equation (2) was solved simultaneously with Equation 
(3) to obtain predictions for C and Cs as functions of time. 
Figure 9(A) displays the results of these computations for three different types of PTX 
formulation (PEG-PLA/CWO/PTX, PEG-PLA/PTX, and Taxol) under various initial 
nanoparticle/PTX dose conditions (0.2, 0.5 and 1.0 mg PTX per cc tumor). Also shown as a 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
guide is the in vitro IC90 value of PTX (i.e., PTX concentration giving rise to 90% cell kill in 
vitro ≈ 90  μg/mL [63]) (horizontal dotted line). As shown in the figure, in the presence of 
CaWO4, radiation triggers PTX release, and the intratumoral PTX concentration showed an 
increasing trend during the initial phase of treatment involving radiation (i.e., for the first 47 
days). This initial boost in PTX dose helped in prolonging the PTX availability within the tumor 
above the therapeutic threshold (e.g., IC90) throughout and beyond the radiotherapy session. 
Also, as can be seen from Figure 9(A), the tumor availability of intratumorally administered PTX 
was significantly influenced by the total initial amount of PTX injected. However, at an identical 
total amount of PTX injected, it was obvious that the PEG-PLA/CWO/PTX system was able to 
maintain the therapeutic PTX level for a much longer period of time (e.g., by > 20 days at 1 
mg/cc PTX dose) than the PEG-PLA/PTX system. 
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Figure 9. (A) Tumor concentrations of PTX released from PEG-PLA/CWO/PTX NPs (solid curves), PEG-
PLA/PTX micelles (dashed curves), and Taxol (PTX in an organic medium) (inset) estimated as functions of time 
following intratumoral injection of these respective formulations at 3 different PTX concentrations of 2, 5 and 10 
mg PTX per cc tumor. In these calculations, it was assumed that tumor received a total 70 Gy 320 keV X-ray dose in 
35 fractions of daily 2 Gy radiation over an initial 47-day period; these daily fractions were given 5 days a week 
with a rest over the weekend similarly to real clinical practice. After Day 47, no further radiation was given. PTX 
release was monitored up to Day 210. The dotted horizontal line represents the IC90 value of PTX measured in vitro 
in HN12 cells and thus the minimum PTX concentration for therapeutic efficacy. In the presence of CWO NPs, PTX 
release was controlled by X-ray irradiation, which enabled sustained release of PTX over a more extended period of 
time. Intratumorally injected Taxol exhibited extremely high PTX concentrations for few hours initially, but PTX 
was completely cleared from the tumor within 36 hours. (B) PTX concentrations in the PLA shell layers of PEG-
PLA/CWO/PTX NPs (solid curves) and PEG-PLA/PTX micelles (dashed curves) calculated as functions of time. 
PTX dose and X-ray radiation parameters used in these calculations were the same as in Figure 9(A). (C) PTX 
concentrations in blood circulation following intratumoral administration of PEG-PLA/CWO/PTX NPs (solid 
curves), PEG-PLA/PTX micelles (dashed curves), and Taxol (PTX in an organic medium) (inset). It was 
simplistically assumed that PTX released from tumor enters the blood circulation, and is eventually cleared from the 
body, e.g., through the kidney and/or liver. Blood concentrations of PTX released from PEG-PLA/CWO/PTX NPs 
and PEG-PLA/PTX micelles were several orders of magnitude lower than the maximum tolerable systemic dose of 
PTX in humans. Intratumoral administration of Taxol exhibited significantly higher blood PTX concentrations for a 
few hours initially. For all calculations, the tumor volume (V) was assumed to be constant/unchanging (= 100 cc). 
 
As shown in Figure 2(B), the PTX-loaded PEG-PLA micelle system exhibited an initial 
burst release; the drug release rate was very high initially (between Days 0 and 10), dropped 
rapidly afterward, and became stagnant for the rest of the period; the PEG-PLA/PTX system 
released about half of the loaded PTX within the first 10 days. Although “burst release” has 
positive aspects (immediate therapeutic effects, easier to overcome drug resistance, etc.), it is 
generally considered a downside because it is difficult to avoid even when such effect is not 
desired [64]. In the presence of co-encapsulated CWO NPs (i.e., in the PEG-PLA/CWO/PTX 
system), the initial burst PTX release phase was not observed (Figure 2(A)). Instead, radiation 
could be used to create a short period of rapid PTX release on demand in a highly controlled 
manner (e.g., > 50% PTX released within a couple of days following 7 Gy radiation). In the 
PEG-PLA/CWO/PTX case, PTX release can be externally controlled by radiation; radiation dose 
and frequency influence PTX release. As demonstrated in Figure 2(A), this radiation-controlled 
PTX release mechanism enabled to maintain PTX tumor levels in the therapeutic range for a 
longer period (e.g., for  > 120 days at 1 mg/cc PTX dose). PTX intratumorally delivered in the 
form of Taxol remained in the tumor, for instance, for < 12 hours at a PTX dose of 10 mg/cc. 
Figure 9(B) displays how the PTX concentration in the PLA layer of a PEG-
PLA/CWO/PTX or PEG-PLA/PTX nanoparticle decreased with time. It was observed that in the 
PEG-PLA/PTX case, the PTX concentration in the PLA layer dropped rapidly in the initial 
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“burst release” phase (0 – 10 days), followed by a second phase of much slower PTX release. In 
the PEG-PLA/CWO/PTX case, radiation enabled to extend the period of rapid release to about 
50 days; about 70% of initially loaded PTX was released from the PLA layer during this rapid 
release (i.e., radiotherapy) period. As a consequence, the tumor PTX concentration was 
maintained at therapeutic levels for a longer period of time (Figure 9(A)). 
It is reasonable to expect that after leaving the tumor, PTX will be mainly absorbed by 
the (blood) circulatory system. It is useful to estimate the PTX concentration in the circulatory 
system; high levels of PTX in the blood could produce systemic toxicity. The PTX concentration 
in the blood can be calculated using the mass balance equation 
     
 (    )
  
                    (4) 
where Cb is the PTX concentration in the blood, Vb is the total blood volume in humans (≈ 4700  
mL in a healthy adult human male [65]), and ke.b is the rate constant for PTX renal clearance in 
humans (≈ 0.336 ± 0.002 h-1 [66]). The results of simulations for three different types of PTX 
formulation (PEG-PLA/CWO/PTX, PEG-PLA/PTX, and Taxol) under various initial 
nanoparticle/PTX dose conditions (0.2, 0.5 and 1.0 mg PTX per cc tumor) are presented in 
Figure 9(C). At an identical initial PTX dose, the PTX concentration in the blood for the PEG-
PLA/CWO/PTX system was higher than that for the PEG-PLA/PTX system because of the 
higher PTX concentration in the tumor in the former situation (Figure 9(A)). A typical PTX dose 
in systemic chemotherapy is about 200 mg/m
2
 in humans [37], which translates into a value of 
about 100 in the units of µg PTX per mL blood (based on the blood volume of 4700 ml for a 
healthy adult human male [65]); this PTX dose level causes dermatological side effects (in skin, 
hair, nail, etc.) in 86.8% of the patients treated, and cognitive/mental health-related problems in 
75.0% of the patients treated [67, 68]. The blood concentration of PTX intratumorally 
administered using the PEG-PLA/CWO/PTX (or PEG-PLA/PTX) delivery system was several 
orders of magnitude below this toxic threshold, which, therefore, supports that the intratumoral 
chemo-radio therapy proposed in this article will not, indeed, produce systemic chemo drug side 
effects. The blood concentration of PTX delivered in the form of Taxol peaked at a few hours 
post-administration and was significantly higher than PTX delivered using the PEG-
PLA/CWO/PTX or PEG-PLA/PTX formulation (inset of Figure 9(C)). 
 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
4. CONCLUSION 
The present study demonstrates radiation-controlled drug release nanoparticle 
formulations (“PEG-PLA/CWO/PTX NPs”) as a means to achieve maximum bioavailability and 
minimum adverse effects of the chemo drugs (PTX), and also their ability to affect head and 
neck cancer cells (in vitro) and xenografts (in vivo). Specifically, the following conclusions can 
be drawn. 
1. Using this novel PEG-PLA/CWO/PTX formulation, an uncontrolled initial burst release 
of PTX can be avoided (Figure 2). Further, radiation can be used to control the PTX 
availability within the tumor in a manner that has not previously been possible; radiation 
triggers the photo-lytic degradation of the PLA polymer and consequently the rapid 
release of PTX from nanoparticles (Figure 2). The PTX release kinetics can be adjusted 
by variation of, for instance, radiation dose (Figure 2). 
2. An in vitro clonogenic survival study in human head and neck cancer HN31 cells 
suggests that concomitant PEG-PLA/CWO/PTX NPs significantly increase the biological 
cell killing effectiveness of X-rays. The SER value was estimated to be 1.40 for the PEG-
PLA/CWO/PTX-treated cells. PTX released from nanoparticles sensitizes HN31 cells to 
low doses of X-ray radiation (Figure 5). 
3. No significant toxicity was observed in HN31 cultures treated with PEG-PLA-
encapsulated CWO NPs (Figure 4). 
4. The efficacy of PTX-loaded PEG-PLA/CWO-based intratumoral chemo-radio therapy 
was evaluated in mouse HN31 tumor xenografts with sub-therapeutic doses of concurrent 
radiation. Concomitant PEG-PLA/CWO/PTX NPs significantly suppressed tumor growth 
(Figure 6) and also significantly enhanced mouse survival relative to X-rays only (Figure 
7). 
5. Following intratumoral administration of PEG-PLA/CWO/PTX NPs in HN31 mouse 
xenografts, time-dependent BD profiles of CWO NPs were determined in tumor and 
major organs (brain, heart, kidney, lung, liver, and spleen). CWO NPs remained localized 
in the tumor for (at least) 30 days (Figure 8). 
6. A multi-compartmental PK model based on experimental rate constant data predicts that 
under the standard radiotherapy dose/fractionation scheme, intratumorally delivered 
PEG-PLA/CWO/PTX NPs maintained the tumor PTX concentration at therapeutic levels 
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over a long period of time that covers the entire radiotherapy treatment period; therefore, 
only a single injection of nanoparticles at the beginning of the radiotherapy session is 
necessary (Figure 9). Also, this PK model demonstrates that the overall intratumoral and 
systemic PTX PK profiles can be adjusted by variations of such parameters as initial 
nanoparticle dose, and radiation dose/frequency. Future work is planned to 
experimentally validate these calculations. 
This radiation-controlled drug release technology will enable patients with advanced solid 
tumors to achieve the benefits of chemo-radio combination treatment with reduced negative 
effects. This approach also presents a new therapeutic option that has not previously been 
available for pateints excluded from conventional chemo-radiotherapy protocols. 
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Highlights 
 Drug-loaded radioluminescent nanoparticles enable radiation-controlled drug release 
 Concurrent drug-loaded radioluminescent nanoparticles enhance radiotherapy efficacy 
 This approach has potential to enhance the therapeutic index for chemo radiation 
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